Keywords: Astellas, Regeneron, Extend VelocImmune license, Financial results
Astellas to pay $295 million to extend license of Regeneron's VelocImmune antibody technology through 2023; Regeneron narrows loss
Article | 29 July 2010
USA-based Regeneron Pharmaceuticals says that Japan’s Astellas has extended through 2023 the non-exclusive license agreement that allows the Japanese drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
